BackBluebird bio Overview

Bluebird bio Current Cash

Bluebird bio's current cash is $79M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$78.74M
↓ 62.86% YoYΔ $-133.30M vs prior year quarter

Peer average

Loading

Bluebird bio Current Cash History

Loading

Bluebird bio vs. peers: Current Cash Comparison

Loading

Bluebird bio Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Bluebird bio (BLUE) FAQ

As of the most recent data (March 2025), BLUE shows a current cash of $79M. That compares with $210M in the prior-year period — down 62.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BLUE's current cash is now $79M (was $210M) — a 62.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Bluebird bio is outperforming or lagging.

Tracking BLUE's current cash over time shows whether Bluebird bio is scaling, shrinking, or reshaping that part of the business. The current reading is $79M That compares with $210M in the prior-year period — down 62.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Bluebird bio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $79M) with ownership activity and broader fundamentals.

Bluebird bio's current cash is $79M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.